Characterization of Biologic Discontinuation Among Pediatric Patients with Crohn’s Disease

Published May 2024

Ali S, Pasternak B, Moses J, Suskind DL, Samson C, Kaplan J, Creps J, Manning L, Baker M, Singer D, Paterl P, Trombler B, Anandakrishnan A, Khorrami C, Feldman M, McGoldrick M, Adler J.

Biologic therapies may effectively treat Crohn’s disease (CD), and pediatric patients who discontinue multiple biologics risk exhausting treatment options. The frequency and context of biologic discontinuation has not been well characterized. We aimed to determine patterns of biologic use, discontinuation, and evaluation in pediatric patients with CD.


High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease

Published March 2024

Dawn R Ebach, Traci W Jester, Joseph A Galanko, Ann M Firestine, Rana Ammoury, Jose Cabrera, Julie Bass, Phillip Minar, Kelly Olano, Peter Margolis, Kelly Sandberg, Tiffany M Linville, Jess Kaplan, Lisa Pitch, Steven J Steiner, Dorsey Bass, Jonathan Moses, Jeremy Adler, Ajay S Gulati, Prateek Wali, Dinesh Pashankar, Anastasia Ivanova, Hans Herfarth, David A Wohl, Keith J Benkov, Jennifer Strople, Jillian Sullivan, Jeanne Tung, Zorela Molle-Rios, Shehzad A Saeed, Athos Bousvaros, Michael D Kappelman

Obesity is common among patients with pediatric Crohn's disease (PCD). Some adult studies suggest obese patients respond less well to anti-tumor necrosis factor (TNF) treatment. This study sought compares anti-TNF response and anti-TNF levels between pediatric patients with normal and high body mass index (BMI).


Real-world effectiveness of ustekinumab and vedolizumab in TNF-exposed pediatric patients with ulcerative colitis

Published March 2024

Patel PV, Zhang A, Bhasuran B, Ravindranath VG, Heyman MB, Verstraete SG, Butte AJ, Rosen MJ, Rudrapatna VA;

Vedolizumab (VDZ) and ustekinumab (UST) are second-line treatments in pediatric patients with ulcerative colitis (UC) refractory to antitumor necrosis factor (anti-TNF) therapy. Pediatric studies comparing the effectiveness of these medications are lacking. Using a registry from ImproveCareNow (ICN), a global research network in pediatric inflammatory bowel disease, we compared the effectiveness of UST and VDZ in anti-TNF refractory UC.


Is it “all in the bag?” Multidisciplinary perspectives on ostomy surgery in pediatric IBD across the ImproveCareNow network

Published January 2024

Jennie G. David, Jennifer Dotson, Laura Mackner

Pediatric inflammatory bowel disease (IBD) is a chronic illness with various treatments, including ostomy surgery. Ostomy‐related medical decision‐making (MDM) is complex for multidisciplinary healthcare professionals (HCPs). This study sought to understand national multidisciplinary HCPs' perceptions about pediatric IBD ostomy surgery in the United States.


Diagnosis change in pediatric inflammatory bowel disease

Published January 2024

Duarte H, Stolfi A, McCall C, Saeed S, Sandberg K.

This study aims to characterize pediatric inflammatory bowel disease (IBD) patients who change diagnosis and describe the characteristics of that change.


Built by Veracity Media on NationBuilder